Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | MLNR | O43193 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AOX1 | Q06278 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.92 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | DRD1 | P21728 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL13697563 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL15472911 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL17119502 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL2328474 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13105406 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13900514 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL14342511 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL13930075 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL20833993 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR | |
| Erythromycin SCHEMBL18211506 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2MLNRABCB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20240316035-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC | 2024-09-26 | — | — | US | disclosed |
| US-11648244-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4140483-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | Auspex Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-11564917-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11446291-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-114796209-A | Deutetrabenazine or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114788824-A | Deutetrabenazine, or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114767672-A | Deutetrabenazine, or compositions comprising deutetrabenazine | 奥斯拜客斯制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11357772-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022096681-A1 | LACTAM-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS | COAVE THERAPEUTICS (FR) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357772-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | CYP3A4 2231/4885KCNH2 789/4885MLNR 2539/4885 |
| US-11446291-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | CYP3A4 2231/4885KCNH2 789/4885MLNR 2539/4885 |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | CYP3A4 304/4885KCNH2 1153/4885MLNR 322/4885 |
| US-11648244-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | CYP3A4 2231/4885KCNH2 789/4885MLNR 2539/4885 |
| US-11564917-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | CYP3A4 2231/4885KCNH2 789/4885MLNR 2539/4885 |
| US-20240316035-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | CYP3A4 2231/4885KCNH2 789/4885MLNR 2539/4885 |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | HTT, HTR2C, NSD1 | CYP3A4 406/4885KCNH2 1392/4885MLNR 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.